Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant factor VIIa.

Michael G Aitken1

  • 1Allamanda Emergency Care Centre, Allamanda Private Hospital, Southport, Queensland, Australia. mgaitken@austarnet.com.au

Emergency Medicine Australasia : EMA
|November 13, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Implementation of Electronic Clinical Decision Support for Radiology Referrals: The Role of Governance, Clinician Engagement and Education.

Emergency medicine Australasia : EMA·2026
Same journal

Low-Value Blood Culture Use in Adult Emergency Department Patients: A Scoping Review.

Emergency medicine Australasia : EMA·2026
Same journal

Coordinating Expertise: Defining the Role of the Modern Trauma Specialist.

Emergency medicine Australasia : EMA·2026
Same journal

Emergency Physicians as Inpatient Specialists: Evolving Models of Trauma Care.

Emergency medicine Australasia : EMA·2026
Same journal

Screening for Asymptomatic Sexually Transmitted Infections in Emergency Departments: An Integrative Review of Public Health Outcomes.

Emergency medicine Australasia : EMA·2026
Same journal

Medical Staffing Models of Inpatient Major Trauma Services in Australia and New Zealand.

Emergency medicine Australasia : EMA·2026
See all related articles

Recombinant factor VIIa (rFVIIa) initiates hemostasis and is approved for hemophilia. Emerging data suggest rFVIIa may treat various bleeding conditions, including trauma and liver disease.

Area of Science:

  • Biochemistry
  • Hematology
  • Pharmacology

Background:

  • Human coagulation factor VII (FVII) is a zymogen that initiates hemostasis upon activation to FVIIa.
  • Recombinant factor VIIa (rFVIIa) is a genetically engineered product initially for hemophilia treatment.
  • rFVIIa has shown potential in diverse bleeding scenarios beyond hemophilia.

Purpose of the Study:

  • To review the physiology of the coagulation pathway.
  • To discuss the role of recombinant factor VIIa (rFVIIa).
  • To focus on the emerging applications of rFVIIa in trauma and non-trauma bleeding, including emergency department use.

Main Methods:

  • Literature review of coagulation physiology.
  • Analysis of case studies and early trial data on rFVIIa.

Related Experiment Videos

  • Discussion of rFVIIa's expanding clinical indications.

    • Main Results:

    • FVIIa is a potent initiator of hemostasis.
    • rFVIIa is effective in hemophilia patients with inhibitors.
    • rFVIIa shows promise in treating bleeding from trauma, surgery, thrombocytopenia, liver disease, and anticoagulant toxicity.

    Conclusions:

    • rFVIIa plays a crucial role in hemostasis.
    • The therapeutic applications of rFVIIa are expanding beyond hemophilia.
    • rFVIIa may be a valuable treatment option for various bleeding emergencies.